Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Pfizer says it will appeal the Aug 1 ruling to Britain’s Supreme Court. Read more at straitstimes.com. Read more at ...

A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

So far, studies have shown that mRNA vaccines -- those made by Pfizer and Moderna -- maintain more than 90% efficacy six months after getting vaccinated. And scientists say it's likely much longer.